What Arlevertan Treats: Main Uses and Benefits

Arlevertan is commonly used for the symptomatic relief of vertigo of various origins in adults. It is applied across conditions characterized by episodic or sudden disturbances of the inner ear's balance function. The therapeutic scope is relevant for managing symptoms related to heightened physiological activity, such as spinning (vertigo), general dizziness, and associated symptoms of nausea and vomiting. This supportive relief may assist with easing the intensity of these symptoms that interfere with daily functioning.

The fixed combination is often used during phases of acute symptom escalation, or conditions associated with acute or disruptive episodes, requiring short-term symptomatic assistance. The medicine is applied in addressing symptom clusters that create noticeable interference with daily stability.

Quick Fact: Relief for Key Symptoms
Symptom focus	Vertigo (spinning), Dizziness, Nausea
Use context	Acute or episodic symptomatic relief
Primary benefit	Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

1. Australian TGA Public Assessment Report

Who can and cannot use Arlevertan

Official regulatory documentation states that Arlevertan is authorized for use only in adults aged 18 years and older. Use in children and adolescents under 18 years is not recommended as safety and efficacy in this age group have not been established.

---

The medicine is contraindicated and must not be used by specific populations due to absolute risk factors. This includes patients with a known hypersensitivity to the active ingredients (cinnarizine, dimenhydrinate) or similar antihistamines. Contraindications also apply to individuals with angle-closure glaucoma, convulsions or suspicion of raised intracranial pressure, and those with alcohol abuse. Organ function determines eligibility, with use prohibited in cases of severe hepatic impairment or severe renal impairment (creatinine clearance le 25 ml/min).

Regulatory documents also state that the medicine should not be used during pregnancy or while breast-feeding. Caution is required in patients with mild to moderate renal impairment, Parkinson’s disease, and other pre-existing conditions that may be aggravated by the drug's properties, such as hypertension or severe coronary heart disease.

Arlevertan (a combination of cinnarizine and dimenhydrinate) can interact with a variety of other medicines and substances, primarily due to its central nervous system (CNS) depressant and anticholinergic properties. It is essential to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal medicines you are taking.

Increased Sedation and Drowsiness

Co-administration with other CNS depressants may significantly enhance the sedative effects of Arlevertan, leading to excessive drowsiness and impaired alertness. These include:

• Alcohol
• Barbiturates (often used to calm or promote sleep)
• Narcotic analgesics (strong painkillers, such as morphine)
• Tranquillizers (used for anxiety and depression)
• Monoamine Oxidase Inhibitors (MAOIs)

Enhanced Anticholinergic Effects

Arlevertan may increase the effects of medicines with anticholinergic properties, potentially worsening side effects like dry mouth, blurred vision, constipation, and urinary retention. Examples include:

• Tricyclic antidepressants
• Atropine and similar muscle-relaxing agents
• Procarbazine (used for some cancers)

Other Significant Interactions

Interaction Type	Affected Medicines	Effect
Cardiovascular	Anti-arrhythmics (drugs to correct heart rhythm problems)	Concurrent use is generally avoided due to potential heart-related risks.
Hypotension Risk	Medicines that lower blood pressure (antihypertensives)	May enhance the blood pressure-lowering effect.
Ototoxicity Masking	Aminoglycoside antibiotics	Arlevertan may mask the warning symptoms (e.g., dizziness) of inner ear damage caused by these antibiotics.
Diagnostic Interference	Allergy skin tests	Arlevertan can interfere with the results of skin tests by suppressing the expected reaction. You should stop taking it a few days before the test.

Arlevertan is a fixed-dose combination product containing two distinct molecules, cinnarizine and dimenhydrinate, which exert independent, yet complementary, pharmacodynamic actions on the vestibular system.

Cinnarizine primarily targets the peripheral vestibular apparatus, functioning as a non-selective antagonist of L-type voltage-gated calcium channels (Cav1). This calcium channel inhibition restricts the influx of Ca^2+ ions into the vestibular sensory hair cells, thereby modulating the signal transmission originating from the inner ear. Additionally, cinnarizine acts as a histamine H1 receptor antagonist and exhibits ancillary antagonism at dopamine D2 and muscarinic acetylcholine receptors.

Dimenhydrinate separates into its components, one of which, diphenhydramine, acts as a first-generation histamine H1 receptor antagonist with high affinity for central nervous system targets. This antagonism blocks the action of histamine at H1 receptors in the vestibular nuclei and the chemoreceptor trigger zone, which are critical nodes in the central vestibular pathway. The combination modulates neural signaling within both the peripheral and central vestibular systems, resulting in reduced overall vestibular output.

How to Use Arlevertan (Cinnarizine/Dimenhydrinate)

Arlevertan is a fixed-combination medicine containing cinnarizine 20 mg and dimenhydrinate 40 mg in a film-coated tablet form.

Official Dosing and Administration

Usage Aspect	Official Instruction
Route of Administration	Oral (swallowed)
Standard Adult Dose	One tablet per dose
Daily Frequency	Three times daily (TID)
Maximum Daily Dose	Do not exceed three tablets in 24 hours
Timing	Must be taken after meals (post-prandially)
Duration of Use	Treatment course is generally limited to four weeks

Procedural Instructions

To ensure correct usage, the tablet must be swallowed whole with a small amount of liquid; it should not be chewed, crushed, or split. Taking the medicine after a meal is mandatory to help minimize potential gastric irritation.

Population Restrictions

Arlevertan is not recommended for use in children and adolescents under 18 years of age. While no specific dose adjustment is listed for the elderly or patients with mild to moderate renal impairment, caution is advised, and the drug is contraindicated in severe hepatic or renal impairment. If a dose is missed, patients should take the next scheduled dose at the usual time and must not take a double dose to compensate.

Research evidence / Overview of Studies for Arlevertan

Evidence for Use in Vestibular Vertigo

The research landscape for this fixed-dose combination primarily rests on Randomized Controlled Trials (RCTs) and Individual Patient Data (IPD) Meta-analyses, which synthesize data from multiple controlled studies. This research was evaluated in adults with conditions associated with acute or disruptive episodes of vertigo, including those arising from central and/or peripheral vestibular disorders.

Researchers designed these studies to examine patient-reported outcomes describing perceived discomfort, primarily using a composite Mean Vertigo Score (MVS) to assess symptom intensity over short timeframes. Data show patterns related to the change in vertigo symptoms over the study period, as well as associated changes measured in outcomes related to physical discomfort, such as nausea and vomiting. The evidence is part of the broader evidence landscape for conditions marked by functional limitations.

Comparison with Other Treatments in Studies

Controlled trials were designed to directly compare the fixed combination against its individual components—cinnarizine alone and dimenhydrinate alone. Research also examined the combination against other treatments used in studies for conditions presenting with cycles of stability and flare-ups, such as betahistine. Comparative research provides data related to short-term changes when this fixed combination was studied for acute vertigo attacks of various origins.

⏱️ Follow-up Duration and Longer-Term Studies

The majority of the core evidence base, including the most rigorous RCTs, observed patient responses over a four-week period. This time interval is relevant in trials assessing short-term or episodic symptom patterns. Some dedicated studies, such as those involving Ménière's disease, extended the observation period for up to 12 weeks.

A key limitation noted in the research is that long-term effects are not fully established and there is limited information for long-term outcomes derived from randomized, controlled studies. Follow-up durations were limited in the pivotal trials, meaning evidence quality varies across studies when considering effects beyond one month.

‍ Evidence in Specific Patient Groups

The fixed combination was evaluated in trials that included a broad spectrum of adults with conditions involving periods of heightened symptoms. The evidence base includes specific studies and subgroup analyses involving older adults (defined in some studies as ≥ 65 years). These subgroups were examined to assess whether the measured outcomes differed based on age or sex.

Research also examined the combination in patients with specific vestibular diagnoses, such as Vestibular Neuritis. Subgroup analyses with respect to age and sex reported that the observed symptom patterns were consistent across these different groups. However, data for certain groups remain insufficient, particularly for pediatric populations or pregnant women.

Research Gaps and Areas of Uncertainty

The primary limitation in the evidence base is that the follow-up durations were limited in the high-level randomized trials, which focused on the management of acute symptoms. This means there is limited information for long-term outcomes or the durability of the reported changes in a controlled research setting.

Scientific literature also discusses an uncertainty related to the long-term use of vestibular suppressants generally. Researchers note that prolonged use may influence the natural process of vestibular compensation (the brain's ability to adapt to inner ear damage). Evidence exploring this specific biological pattern in controlled trials of the fixed combination is limited.

Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. Australian Public Assessment Report (AusPAR): Cinnarizine with dimenhydrinate
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index N07CA52

Common questions about Arlevertan (FAQ)

---

Q: Is Arlevertan the same as other medicines for dizziness?

Arlevertan is described in official regulatory documents as a fixed-dose combination medicine. This means it contains two distinct active ingredients—cinnarizine (a calcium antagonist) and dimenhydrinate (an antihistamine)—in one tablet. The combination is used together for a complementary effect and has been described in official information as being more effective than when the individual components are used alone in studies.

---

Q: Why is the drug used for 'vertigo' and not just 'dizziness'?

The official indication for the medicine is for the symptomatic treatment of vertigo in adults, which official product information sometimes describes as the sensation of dizziness or 'spinning,' along with associated nausea. The medicine is authorized for this specific set of symptoms as defined in regulatory documents.

---

Q: Is Arlevertan taken to prevent vertigo or to treat an episode?

The official regulatory indication states that Arlevertan is used for the symptomatic treatment of vertigo. This means its primary purpose, as described in authorized documents, is to help relieve the symptoms of an episode.

---

Q: What does official information say about the use of Arlevertan for motion sickness?

While motion sickness can include symptoms like nausea, the official product information lists the medicine's use for the symptoms of vertigo and associated discomforts such as nausea (feeling sick). The medicine is authorized for this specific purpose.

---

Q: What is the difference between Arlevertan and just taking Cinnarizine?

Arlevertan is a fixed combination of cinnarizine and dimenhydrinate. Official regulatory information states that the two substances are used together because research examined their use and found that the combination demonstrated patterns of response beyond those observed when cinnarizine or dimenhydrinate was used alone.

---

Q: Is Arlevertan known by a different brand name in other countries?

The fixed combination of cinnarizine and dimenhydrinate is marketed under different brand names globally. In some regions, the combination product may be known by a different name, such as 'Arlevert' in various European countries.

---

Q: Is it true that Arlevertan is only approved in certain regions?

Official product information and specific brand names for this fixed combination are primarily available and authorized in specific regulatory regions, such as various countries within Europe.

---

Q: Are there any laboratory tests that Arlevertan can interfere with?

According to official documents, the medicine can interfere with the results of certain diagnostic procedures. Specifically, Arlevertan can affect allergy skin tests by potentially suppressing the expected reaction.

---

Q: Does Arlevertan contain gluten or lactose?

The official list of other ingredients (excipients) in Arlevertan tablets includes substances like microcrystalline cellulose, maize starch, talc, hypromellose, colloidal anhydrous silica, magnesium stearate and croscarmellose sodium. This list defines the formulation described in the official product information.

---

Q: Can Arlevertan cause changes in mood or anxiety?

Official regulatory documents list nervousness as an uncommon side effect of this medicine, meaning it may affect up to 1 in 100 people. Side effects are listed and classified by frequency in the official safety information.

---

Q: Are there any known severe side effects of Arlevertan?

Official prescribing information lists rare side effects, which may affect up to 1 in 1,000 people. These rare effects include allergic reactions and impaired vision.

---

Q: Is it possible to be allergic to Arlevertan?

Official safety information states that known hypersensitivity (a severe allergic reaction) to the active ingredients or similar antihistamines is a contraindication, meaning the medicine must not be used. Allergic reactions are also listed as a rare side effect.

---

Q: Is Arlevertan used to treat the cause of vertigo or just the symptom?

The official indication for Arlevertan is for the symptomatic treatment of vertigo. This describes its role in the symptomatic treatment of vertigo, which means it is used to help relieve the symptoms, not to address the underlying cause of the condition itself.

How to Store and Dispose of Arlevertan?

Official regulatory documents define specific, non-advisory rules for storing and discarding Arlevertan (cinnarizine/dimenhydrinate) tablets.

Storage Requirements

• Temperature Control: The medicine must be stored at a temperature not exceeding 30 C. No other special environmental conditions, such as protection from light or moisture, are explicitly mandated.
• Child Safety: The tablets must be kept out of the sight and reach of children.
• Stability: The medicine should not be used after the expiry date printed on the blister and carton.

Disposal Instructions

• Wastewater Prohibition: Arlevertan must not be disposed of via wastewater (i.e., flushing down a toilet or pouring down a sink).
• Unused Product: Any expired or unused product must be discarded in accordance with local waste requirements, typically by returning it to a pharmacy for appropriate pharmaceutical waste handling.